Exactech Announces Successful First Revision Knee Replacement Surgery with Truliant® Instrumentation
November 01 2017 - 12:15PM
Business Wire
System to Debut at the AAHKS Annual Meeting,
Booth #908 in Dallas
Exactech (Nasdaq: EXAC), a developer and producer of bone and
joint restoration products and biologic solutions for extremities,
knee and hip, is pleased to announce that the first revision knee
surgery was performed using the company's award-winning Truliant®
instrumentation. Orthopaedic surgeons will have a chance to
experience the Truliant primary and revision systems through live
mechanical demonstrations Nov. 2-5 at the American Association of
Hip and Knee Surgeons (AAHKS) Annual Meeting, Booth #908 in Dallas,
Texas.
The first surgery was performed by revision knee replacement
specialist Ronald Hillock, MD, at the Nevada Orthopedic and Spine
Center in Las Vegas. According to Dr. Hillock, “The case ran
smoothly, and I was able to re-establish the patient’s joint line
in just over an hour. Truliant is a well-thought-out, comprehensive
system that allowed me to easily position the implant in the
optimal position for the patient. The new offset couplers and
metaphyseal cones allows for managing the complexities of implant
fixation and bone loss.”
Developed through close collaboration with a team of design
surgeons and Exactech engineers, Truliant supports both mechanical
and computer-assisted surgical approaches and now addresses the
continuum of total knee arthroplasty – from primary to
revision.
“In designing Truliant, we were met with the paradox of trying
to be simple and easy to understand, while still providing the
surgeon and patient with all the options they need,” said Daniel C.
Allison, MD, oncologic orthopaedic surgeon and Truliant design team
member. “I think Exactech did a great job of bringing those things
together and threading that needle, so that everything is intuitive
without being overly complex. Combining that simplicity, while
maintaining a wide variety of options was a hard challenge, but
Exactech mastered it beautifully.”
The Truliant primary knee system made its clinical debut in May
and has been used in more than 600 surgeries during the pilot
launch. Both the primary and revision systems are expected to have
full U.S. market availability in 2018. For more information, visit
www.TruliantKnee.com.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech can be found
at http://www.exac.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171101006434/en/
ExactechJody Phillips, 352-377-1140Executive Vice President of
Finance & Chief Financial OfficerorExactechPriscilla Bennett,
352-377-1140Priscilla@exac.com
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Nov 2023 to Nov 2024